All In Biotech

Drug Trial Radar · NCT04494425

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 866 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

866

Actual

Start

Jul 24, 2020

Primary completion

Mar 18, 2024

Study completion Jun 19, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jul 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 105 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Conditions

  • Advanced or Metastatic Breast Cancer

Interventions

  • Trastuzumab deruxtecanDrug

    Trastuzumab deruxtecan by intravenous infusion

  • CapecitabineDrug

    Investigator's choice standard of care single agent chemotherapy; capecitabine tablets will be given orally.

  • PaclitaxelDrug

    Investigator's choice standard of care single agent chemotherapy; paclitaxel by intravenous infusion.

  • Nab-PaclitaxelDrug

    Investigator's choice standard of care single agent chemotherapy; nab-paclitaxel by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low PopulationTime frame: Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)

Locations

293 sites in 28 countries. Site status is shown where the registry gives one.

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Springdale, Arkansas

  • Research Site

    Duarte, California

  • Research Site

    Los Angeles, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Lakewood, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Kansas City, Kansas

  • Research Site

    Louisville, Kentucky

  • Research Site

    Bethesda, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Summit, New Jersey

  • Research Site

    Westbury, New York

  • Research Site

    Columbus, Ohio

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Austin, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Norfolk, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Córdoba, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Adelaide, Australia

  • Research Site

    Birtinya, Australia

  • Research Site

    Darlinghurst, Australia

Showing 40 of 293 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.